WAYNE, Pa., July 6 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced that Robert O'Connor has been appointed
Chief Financial Officer effective June 30, 2006. Mr. O'Connor joins Escalon
Medical Corp. from BDO Seidman, LLP where he served as a senior manager.
His prior experience includes both public and private accounting roles as a
manager at PricewaterhouseCoopers, L.L.P. in Philadelphia, Pennsylvania,
where he served in the middle market advisory services group, and positions
of controller and chief financial officer for two publicly traded middle
market technology and manufacturing companies.
    Mr. O'Connor holds an MBA from Rutgers University - Graduate School of
Management and a B.S. from Kean University. He is a certified public
accountant and a member of the American Institute of Certified Public
Accountants (AICPA).
    About Escalon
    Founded in 1987, Escalon develops markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices. Drew, which operates as a separate business unit, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology,
as well as veterinary hematology and blood chemistry. Escalon seeks to
utilize strategic partnerships to help finance its development programs and
is also seeking acquisitions to further diversify its product line to
achieve critical mass in sales and take better advantage of the Escalon's
distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania
and manufacturing operations in Long Island, New York, New Berlin,
Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.
    Note: This press release contains statements that are considered
forward- looking under the Private Securities Litigation Reform Act of
1995, including statements about Escalon's future prospects. They are based
on the Escalon's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether Escalon is able to improve upon the
operations of Escalon's business units, including, the integration of
Drew's operations, generate cash and identify, finance and enter into
business relationships and acquisitions, integrate and leverage those
business relationships and acquisitions, uncertainties and risks related to
new product development, commercialization, manufacturing and market
acceptance of new products, marketing acceptance of existing products in
new markets, the continuity of royalty revenue, litigation and
non-recurring expenses, research and development activities, including
failure to demonstrate clinical efficacy, delays by regulatory authorities,
scientific and technical advances by Escalon or third parties, introduction
of competitive products, third party reimbursement and physician training
as well as general economic conditions. Further information about these and
other relevant risks and uncertainties may be found in Escalon's report on
Form 10-K, and its other filings with the Securities and Exchange
Commission, all of which are available from the Commission as well as other
sources.

Link to this page: